This clinical trial, known as the RiCOTTA trial, is focused on studying the treatment of prosthetic joint infection, which is an infection that can occur in people who have had joint replacement surgery, such as a hip or knee replacement. The study is comparing two different treatment approaches during the oral medication phase. One approach uses a single medication called clindamycin, while the other uses a combination of medications, including rifampicin and a group of antibiotics known as fluoroquinolones. The goal is to determine if the single medication approach is as effective as the combination treatment.
Participants in the study will receive one of these treatments after undergoing a procedure called DAIR, which stands for Debridement, Antibiotics, and Implant Retention. This procedure involves cleaning the infected area, using antibiotics, and keeping the joint implant in place. The study will follow participants for a period of time to monitor their recovery and check for any signs of infection returning. The effectiveness of the treatment will be assessed 15 months after the DAIR procedure, which is one year after finishing the antibiotic treatment.
Throughout the study, various aspects will be evaluated, such as the participants’ quality of life, any side effects from the antibiotics, and the occurrence of any new infections. The study will also look at whether any bacteria develop resistance to rifampicin in cases where the treatment does not work as expected. The trial is expected to continue until 2028, with the aim of providing valuable information on the best treatment approach for prosthetic joint infections.
The Netherlands 
